(PharmaNewsWire.Com, January 07, 2017 ) The report provides comprehensive information on the therapeutics under development for Nicotine Addiction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Nicotine Addiction and features dormant and discontinued projects.
This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
- The report provides a snapshot of the global therapeutic landscape of Nicotine Addiction - The report reviews pipeline therapeutics for Nicotine Addiction by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Nicotine Addiction therapeutics and enlists all their major and minor projects - The report assesses Nicotine Addiction therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Nicotine Addiction
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Nicotine Addiction - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Nicotine Addiction pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Key Companies profiles Addex Therapeutics Ltd Astraea Therapeutics, LLC Cerecor Inc. Embera NeuroTherapeutics, Inc. Hager Biosciences, LLC Heptares Therapeutics Limited Omeros Corporation RTI International
Few Points from List of Tables Number of Products under Development for Nicotine Addiction, H1 2016 8 Number of Products under Development for Nicotine Addiction - Comparative Analysis, H1 2016 9 Number of Products under Development by Companies, H1 2016 10 Number of Products under Investigation by Universities/Institutes, H1 2016 11 Comparative Analysis by Clinical Stage Development, H1 2016 12 Comparative Analysis by Early Stage Development, H1 2016 13 Products under Development by Companies, H1 2016 14 Products under Investigation by Universities/Institutes, H1 2016 15 Nicotine Addiction - Pipeline by Addex Therapeutics Ltd, H1 2016 16 Nicotine Addiction - Pipeline by Astraea Therapeutics, LLC, H1 2016 17 Nicotine Addiction - Pipeline by Cerecor Inc., H1 2016 18 Nicotine Addiction - Pipeline by Embera NeuroTherapeutics, Inc., H1 2016 19 Nicotine Addiction - Pipeline by Hager Biosciences, LLC, H1 2016 20 Nicotine Addiction - Pipeline by Heptares Therapeutics Limited, H1 2016 21 Nicotine Addiction - Pipeline by Omeros Corporation, H1 2016 22 Nicotine Addiction - Pipeline by RTI International, H1 2016 23 Assessment by Monotherapy Products, H1 2016 24 Assessment by Combination Products, H1 2016 25 Number of Products by Stage and Target, H1 2016 27
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including: